Abstracts Archive - Page 796 of 2607 - ACR Meeting Abstracts

Abstract Number: 1363 • ACR Convergence 2021
Identification of PsA Phenotypes with Machine Learning Analytics Using Data from a Phase 3 Clinical Trial Program of Guselkumab in a Bio-naïve Population of Patients with PsA
Pascal Richette¹, Marijn Vis², Sarah Ohrndorf³, William Tillett⁴, Marlies Neuhold⁵, Michel van Speybroeck⁶, Elke Theander⁷, Wim Noel⁸, May Shawi⁹, Alexa Kollmeier¹⁰ and Alen Zabotti¹¹, ¹Lariboisiere Hospital, Paris, France, ²Erasmus MC, Badhoevedorp, Netherlands, ³Charité University Medicine Berlin, Berlin, Germany, ⁴Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁵Janssen-Cilag, Zug, Switzerland, ⁶Janssen Pharmaceutica, Belgium, Belgium, ⁷Janssen Cilag, Lund, Sweden, ⁸Janssen Pharmaceutica, Vilvoorde, Belgium, ⁹Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ¹⁰Janssen Research & Development, LLC, La Jolla, CA, ¹¹University of Udine, Udine, Italy
Background/Purpose: Psoriatic arthritis (PsA) is mainly described based on the individual domains or clinical components of the disease.1,2 The aim of this post hoc analysis…
Abstract Number: 1364 • ACR Convergence 2021
Autologous Hematopoietic Stem Cell (HSC) Transplantation for Systemic Sclerosis, North American Registry: Updated Outcomes and the Impact of CD34+ HSC Enrichment
George Georges¹, Keith Sullivan², Dinesh Khanna³, Matthew Mei⁴, Maureen Mayes⁵, Dan Furst⁶, Mark Wener⁷, Suzanne Kafaja⁸, Gwynn Long², Vaishali Sanchorawala⁹, Kareem Jamani¹⁰, Attaphol Pawarode³, Ashish Masurekar¹¹, Brian Lam¹², Richard Nash¹³, Marcin Trojanowski⁹, Chitra Hosing¹⁴, Philip Clements¹⁵, Tanya Helms², Bernadette McLaughlin¹⁶, Linda Griffith¹⁷, Kyle Hebert¹⁸, Mary Eapen¹⁸, Jan Storek¹⁰ and Harold Atkins¹¹, ¹Fred Hutchison Cancer Research Center and University of Washington, Seattle, WA, ²Duke University School of Medicine, Durham, NC, ³University of Michigan, Ann Arbor, MI, ⁴City of Hope Comprehensive Cancer Center, Duarte, CA, ⁵Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, ⁶University of California Los Angeles, Los Angeles, CA, ⁷University of Washington, Seattle, WA, ⁸University of California Los Angeles Division of Rheumatology, Los Angeles, CA, ⁹Boston University School of Medicine, Boston, MA, ¹⁰University of Calgary, Calgary, AB, Canada, ¹¹Ottawa Hospital Research Institute, Ottawa, ON, Canada, ¹²University of Texas McGovern Medical School, Houston, TX, ¹³Colorado Blood Cancer Institute, Denver, CO, ¹⁴University of Texas MD Anderson Cancer Center, Houston, TX, ¹⁵University of California Los Angeles School of Medicine, Department of Rhemumatology, Los Angeles, CA, ¹⁶Fred Hutchison Cancer Research Center, Seattle, WA, ¹⁷Division of Allergy Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, ¹⁸Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Autologous hematopoietic stem cell transplantation (AHSCT) is now established as a preferred standard of care treatment for patients with severe scleroderma with internal organ…
Abstract Number: 1365 • ACR Convergence 2021
Release of High-Mobility Group Box-1 After an Raynaud’s Attack Potentially Leads to Fibroblast Activation and Interferon-γ Induced Protein-10 Production in Systemic Sclerosis
Isabella Atzeni¹, Yehya Al-Adwi², Berber Doornbos-van der Meer², Amel Eman Abdulle², Anniek Van Roon², Alja J. Stel², Harry Van Goor², Andries Smit², Johanna Westra² and Douwe J Mulder², ¹University of Groningen, University Medical Centre Groningen, Groningen, Groningen, Netherlands, ²University of Groningen, University Medical Centre Groningen, Groningen, Netherlands
Background/Purpose: Raynaud’s Phenomenon (RP) leading to repetitive ischaemia and reperfusion (IR) stress, is the first recognisable sign of systemic sclerosis (SSc). Although RP has been…
Abstract Number: 1366 • ACR Convergence 2021
The Use of Lipid-Lowering Agents in Systemic Sclerosis: Is There a Relationship with Prevalence of Digital Ulcers and Overall Survival?
Olivia Sallis¹, Dylan Hansen², Kathleen Morrisroe³, Wendy Stevens³, Mandana Nikpour⁴ and Susanna Proudman⁵, ¹Royal Adelaide Hospital, Adelaide, Australia, ²St. Vincent’s Hospital Melbourne, Victoria, Australia, Adelaide, Australia, ³St Vincent's Hospital, Melbourne, Australia, ⁴University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ⁵University of Adelaide, Medindie, Australia
Background/Purpose: Digital ulcers (DU) are common in systemic sclerosis (SSc). Vasodilator therapies have limited benefit in prevention and promoting healing. Lipid-lowering agents (LLAs) such as…
Abstract Number: 1367 • ACR Convergence 2021
Associations of Esophageal Dysmotility Patterns with Extra-intestinal Features in Patients with Systemic Sclerosis
Ana Tucker¹, Jamie Perin², Elizabeth Volkmann³, Ami Shah⁴, John Pandolfino⁵ and Zsuzsanna McMahan⁴, ¹Medical University of South Carolina, Charleston, SC, ²Johns Hopkins University, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, University of California, David Geffen School of Medicine, Los Angeles, CA, ⁴Johns Hopkins Rheumatology, Baltimore, MD, ⁵Northwestern University, Chicago, IL
Background/Purpose: The gastrointestinal (GI) tract is the most commonly affected internal organ in systemic sclerosis (SSc). SSc GI disease is heterogeneous, with some patients experiencing…
Abstract Number: 1368 • ACR Convergence 2021
Characterising Exercise Capacity in Systemic Sclerosis Using Cardiac Magnetic Resonance Imaging, Skeletal Muscle Imaging and Cardiopulmonary Exercise Testing
Laura Ross¹, Benedict Costello², Dylan Hansen³, Anniina Lindqvist², Zoe Brown⁴, Andrew Burns⁴, David Prior⁴, Wendy Stevens⁴, Marcus Pianta⁴, Warren Perera⁴, Andre La Gerche² and Mandana Nikpour¹, ¹University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ²Baker Heart and Diabetes Institute, Melbourne, Australia, ³St. Vincent’s Hospital Melbourne, Victoria, Australia, Adelaide, Australia, ⁴St Vincent's Hospital, Melbourne, Australia
Background/Purpose: Impaired exercise capacity contributes to functional impairment, negatively impacting individuals’ quality of life. Functional impairment is notable from early in the disease course of…
Abstract Number: 1369 • ACR Convergence 2021
Adipose Tissue-Derived Stromal Vascular Fraction Plus Fat Grafts for Hand Therapy in Patients with Systemic Sclerosis. a Randomized Controlled Clinical Trial
Martín Iglesias¹, Iván Torre-Villalvazo¹, Armando Tovar-Palacio¹, Alejandro Zentella-Dehesa¹, Patricia Butrón-Gandarillas¹, Marta Durand-Carbajal¹, Erik Torre-Anaya², Martha Guevara² and Tatiana Rodriguez-Reyna², ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
Background/Purpose: Adipose tissue-derived Stromal Vascular Fraction (ADSVF) has been proposed as regenerative treatment for hand deformities and digital ulcer healing in patients with Systemic Sclerosis…
Abstract Number: 1370 • ACR Convergence 2021
Complement Factor D and Factor H Represent Disease and Severity Biomarkers for Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)
Roberta G Marangoni¹, Changyong Feng¹, Ashley Frazer-Abel², Stephen Tomlinson³, Amy Wielgosz¹, Katie Lutz⁴, Michael Pauciulo⁴, William Nichols⁴, V. Michael Holers⁵, Christopher Ritchlin⁶, R James White III¹ and Benjamin Korman¹, ¹University of Rochester, Rochester, NY, ²University of Colorado Denver, Colorado, CO, ³Medical University of South Carolina, Charleston, SC, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵University of Colorado, Denver, CO, ⁶Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe vascular complication of systemic sclerosis (SSc) and a major cause of mortality. Despite significant advances in the…
Abstract Number: 1371 • ACR Convergence 2021
Symptom Management in Systemic Sclerosis: A Pilot Study of a Web-based Intervention Using Peer-Health Coaches
Susan Murphy¹, Yen Chen², Mary Alore², Sheri Hicks² and Dinesh Khanna², ¹University of Michigan, Grosse Ile, MI, ²University of Michigan, Ann Arbor, MI
Background/Purpose: People with systemic sclerosis (SSc) have a high burden of chronic symptoms that have dramatic effects on function and quality of life. Fatigue, along…
Abstract Number: 1372 • ACR Convergence 2021
Outcomes and Risk Factors for Respiratory Failure in Patients with Scleroderma Associated with ILD
Soumyasri Kambhatla¹, Augustine Manadan² and Amy Trang², ¹Rush University, Chicago, IL, ²Rush University Medical Center, Chicago, IL
Background/Purpose: Scleroderma is associated with underlying ILD. About 48% those with diffuse cutaneous SSc and 26% of those with limited cutaneous SSc were found to…
Abstract Number: 1373 • ACR Convergence 2021
Paraoxonase-1: Potential Novel Marker of Disease Extent and Activity in Systemic Sclerosis
Suzanne Kafaja¹, Isela Valera², Yossra Suliman³, Mohamed Alemam⁴, Rosha Mamita⁵, Jennifer Wang⁵, Ani Shahbazian⁶, Philip Clements⁷ and Christina Charles-Schoeman⁶, ¹University of California Los Angeles Division of Rheumatology, Los Angeles, CA, ²Florida Universtity- College of Health and Human Sciences, Talahhasse, FL, ³Department of Clinical Pathology, Qena Faculty of Medicine, Assiut, Egypt, ⁴Department of Pathology< Qena Faculty of Medicine, South Valley University,, Assiut, Egypt, ⁵University of California Los Angeles, Los Angeles, CA, ⁶Department of Medicine, University of California, Los Angeles, Los Angeles, CA, ⁷University of California Los Angeles School of Medicine, Department of Rhemumatology, Los Angeles, CA
Background/Purpose: Our understanding of the pathogenesis of systemic sclerosis (SSc) continues to evolve. Oxidative stress has been implicated in the pathophysiology of disease, but minimal…
Abstract Number: 1374 • ACR Convergence 2021
A Deep Neural Network Classifier to Identify Inflammatory Systemic Sclerosis Patients from Histological Images
Yiwei Yuan¹, Robert Lafyatis², Johann Gudjonsson³, Dinesh Khanna⁴ and Michael Whitfield⁵, ¹Dartmouth College, Hanover, NH, ²University of Pittsburgh, Pittsburgh, PA, ³Department of Dermatology, University of Michigan, Ann Arbor, MI, ⁴University of Michigan, Ann Arbor, MI, ⁵Geisel School of Medicine, Lebanon, NH
Background/Purpose: Systemic sclerosis (SSc) patients can be divided into four molecular subsets (inflammatory, fibroproliferative, limited and normal-like) identifiable with gene expression in skin and peripheral…
Abstract Number: 1375 • ACR Convergence 2021
Improvement in Overall Survival, Skin Fibrosis and Lung Function with Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis
Nancy Maltez¹, Mianbo Wang², Georges Wells³, Peter Tugwell¹, Murray Baron⁴, Zora Marjanovic⁵, Pauline Lansiaux⁶, Dominique Farge⁶ and Marie Hudson⁷, ¹The Ottawa Hospital, Ottawa, ON, Canada, ²Lady Davis institute for Medical Research, Montréal, QC, Canada, ³University of Ottawa, Ottawa, ON, Canada, ⁴Jewish General Hospital, Montréal, QC, Canada, ⁵Hopital Saint-Antoine, Paris, France, ⁶8. Centre de Référence des Maladies auto-immunes systémiques Rares d’Ile-de-France, Paris, France, ⁷McGill University, Montréal, QC, Canada
Background/Purpose: Systemic sclerosis (SSc) is a chronic disease characterized by vasculopathy, inflammation and fibrosis. Rheumatologists have limited options to effectively treat rapidly progressive disease. There…
Abstract Number: 1376 • ACR Convergence 2021
Outcome Reporting in Systemic Sclerosis-Related Digital Ulcers: A Scoping Review
Michael Hughes¹, Nancy Maltez², Edith Brown³, Virginia Hickey⁴, Heiyoung Park⁵, Beverley Shea², John Pauling⁶, Susanna Proudman⁷, Peter Merkel⁸ and Ariane Herrick⁹, ¹Tameside and Glossop Integrated NHS Foundation Trust, Manchester, United Kingdom, ²University of Ottawa, Ottawa, ON, Canada, ³n/a, Manchester, United Kingdom, ⁴n/a, Adelaide, Australia, ⁵5. National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, ⁶Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁷University of Adelaide, Medindie, Australia, ⁸University of Pennsylvania, Philadelphia, PA, ⁹University of Manchester, Salford, United Kingdom
Background/Purpose: Digital ulcers (DUs) are a major cause of pain and disability in patients with systemic sclerosis (SSc). Despite the availability of a range of…
Abstract Number: 1377 • ACR Convergence 2021
Assessment of Autoantibodies and Clinical Associations in SSc Patients with ANA Positivity & Negative for Prototypic Autoantibodies
Karen Kruzer¹, Roberta G Marangoni¹, Ilana Heckler², Aya Elhage², Varga John³, Monique Hinchcliff⁴, Mary Carns⁵, Kathleen Aren⁵, Amy Wielgosz¹, Marc Nuzzo⁶, Iswariya Venkataraman² and Benjamin Korman¹, ¹University of Rochester, Rochester, NY, ²EUROIMMUN US, Mountain Lakes, NJ, ³University of Michigan, Ann Arbor, MI, ⁴Yale School of Medicine, Westport, CT, ⁵Northwestern University Division of Rheumatology, Chicago, IL, ⁶Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Systemic sclerosis (SSc) is a clinically heterogenous disease typically characterized by a positive ANA (ANA+), and prototypical antibodies including anti-centromere, anti-topoisomerase, and anti-RNA polymerase…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].